Todos os estudos
AutorizadoFase I e Fase II (Integrada) - Primeira administração em humanosIntervencionista

Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of rAAVOlig001-ASPA Gene Therapy for Treatment of Children with Typical Canavan Disease

This study is testing a new gene therapy called rAAV-Olig001-ASPA for children with Canavan disease. Canavan disease is a serious condition that affects the brain as children grow. The aim of this study is to see how safe the treatment is and if it can help reduce a chemical called NAA, which builds up in the brains of children with Canavan disease. High NAA levels are thought to cause many of the problems seen in the condition. Researchers will also be looking at whether the gene therapy helps children’s movement, language, and other developmental skills over time. This is an early study, meaning it's an important first step in understanding if this new treatment could be helpful.

Em resumo

Status
Autorizado
Fase
Fase I e Fase II (Integrada) - Primeira administração em humanos
Patrocinador
Myrtelle Inc.
Meta de inscrição
7
Iniciar
18 Fev 2026

Sobre o que é este estudo?

This clinical trial is designed to investigate a new treatment for Canavan disease, a rare and serious genetic condition that affects the brain. In Canavan disease, the body can't properly break down a chemical called N-Acetylaspartate (NAA), leading to its build-up in the brain. This build-up causes damage to the brain's white matter, which is important for communication between different parts of the brain and the rest of the body. Children with Canavan disease often experience problems with movement, speech, and overall development.

The new treatment being tested is a gene therapy called rAAV-Olig001-ASPA. Gene therapy aims to fix the root cause of certain diseases by delivering healthy copies of genes into the body. In this case, the therapy is given directly into the brain. The hope is that this treatment will help the brain produce the missing enzyme needed to break down NAA, thereby reducing its harmful levels.

This study is in its early stages (Phase 1/2), which means it's an important step where researchers carefully assess the safety of the treatment and start to look for early signs of how well it works. They will be measuring the levels of NAA in the brain and urine, as well as carefully observing children's development, including their movement, language, and thinking skills, to see if the treatment makes a positive difference.

Pontos principais

  • This study is testing a new gene therapy for Canavan disease.
  • The treatment is given once, directly into the brain.
  • Researchers will check if it reduces a harmful chemical (NAA) in the brain.
  • They also want to see if it helps with movement and development.
  • It's an early-stage study, focused on safety and early signs of how well it works.

Quem pode ser elegível?

This study is looking for children with typical Canavan disease. Both boys and girls can take part, and there are no specific age limits listed in the initial information, meaning children across a range of ages might be considered.

To be eligible, a child would need to have a confirmed diagnosis of Canavan disease. The medical team would conduct a thorough review to make sure the child meets all the necessary health criteria for participating in a gene therapy study.

Because this is a specific treatment for a specific condition, the study will only be suitable for children who have Canavan disease and meet all other health requirements set by the researchers.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Does my child have a confirmed diagnosis of Canavan disease?
  2. Is my child generally healthy enough to participate in a medical study?
  3. Am I able to commit to several follow-up visits and assessments?
  4. Am I comfortable with my child receiving a new type of treatment into their brain?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If your child takes part in this study, they would receive a single dose of the gene therapy, which is given into the brain. After the treatment, there would be several follow-up visits over a period of time, at least up to 12 months. These visits are important for the medical team to monitor your child's health and see how the treatment is working.

During these visits, your child would have various assessments. This would include tests to measure chemical levels in their brain fluid (CSF) and urine, and special brain scans called SyMRI to check brain health. They would also have regular checks of their physical development, like movement skills (Gross Motor Function Measure-88), and assessments of their language, thinking, and other developmental abilities (using tests like the MSEL). The total duration of participation and specific schedule of visits would be fully explained by the study team.

Riscos e benefícios potenciais

Taking part in a trial like this offers the potential for your child to receive a new treatment that might help with their Canavan disease, and it also contributes valuable information for future treatments. However, as with any new medical treatment, there are potential risks, side effects, or discomforts that the study team would explain in detail. These could include risks associated with receiving treatment directly into the brain, or possible side effects from the gene therapy itself. You would be fully informed about these risks and always have the right to withdraw your child from the study at any time, for any reason, without affecting their future medical care.

Localizações (1)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    França

Perguntas frequentes

O que é terapia genética?

Gene therapy aims to fix diseases by giving the body healthy copies of genes to replace faulty ones. In this study, it's designed to help children with Canavan disease.

What is NAA?

NAA (N-Acetylaspartate) is a chemical that builds up in the brains of children with Canavan disease. High levels of NAA are thought to cause brain damage and developmental problems.

How is the treatment given?

The gene therapy is given as a single dose directly into your child's brain. This helps the treatment get to where it's needed most.

What will researchers be looking for?

Researchers will check if the treatment reduces harmful NAA levels. They'll also monitor your child's movement, language, and overall development to see if improvements occur.

Is this treatment available to everyone?

No, this is a clinical trial, meaning it's still being tested. Only children who meet specific health and diagnostic criteria for Canavan disease can take part.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.